title: Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
authors.affiliation: Department of Surgery, Leicester General Hospital, University of Leicester, United Kingdom.
authors.forename: E O
authors.initials: EO
authors.lastname: Kehinde
authors.forename: J
authors.initials: J
authors.lastname: Feehally
authors.forename: S D
authors.initials: SD
authors.lastname: Scriven
authors.forename: P S
authors.initials: PS
authors.lastname: Veitch
authors.forename: P R
authors.initials: PR
authors.lastname: Bell
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004351:Drug Resistance; D006084:Graft Rejection / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D012189:Retrospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone